Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Revenue (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Revenue for 11 consecutive years, with -$298000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 177.0% to -$298000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $400000.0, a 98.97% decrease, with the full-year FY2025 number at $400000.0, down 98.95% from a year prior.
  • Revenue was -$298000.0 for Q3 2025 at Cartesian Therapeutics, down from $298000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $39.3 million in Q2 2022 to a low of -$836000.0 in Q4 2024.
  • A 5-year average of $13.7 million and a median of $8.3 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 533.85% in 2024, then crashed 177.0% in 2025.
  • Cartesian Therapeutics' Revenue stood at $29.9 million in 2021, then tumbled by 43.9% to $16.8 million in 2022, then plummeted by 50.78% to $8.3 million in 2023, then crashed by 110.11% to -$836000.0 in 2024, then soared by 64.35% to -$298000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Revenue are -$298000.0 (Q3 2025), $298000.0 (Q2 2025), and $400000.0 (Q1 2025).